A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem

ISSN: 1873-4316 (Online)
ISSN: 1389-2010 (Print)

Volume 18, 15 Issues, 2017

Download PDF Flyer

Current Pharmaceutical Biotechnology

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 152nd of 255 in Pharmacology & Pharmacy
  • 213th of 290 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Zeno Foldes-Papp
Urban Clinical Center Soltau
University teaching hospital of Hamburg

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.802
5 - Year: 2.327

A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem

Current Pharmaceutical Biotechnology, 15(8): 685-690.

Author(s): Yuanxing Wu, Kai Chen, Zhonghua Shi and Qiang Wang.

Affiliation: ICU, Beijing Tiantan Hospital, The Capital Medical University, Beijing 100050, China.


Objective: We sought to evaluate the safety of imipenem and meropenem in the treatment of infections in neurosurgical patients. Methods: An observational retrospective study was conducted of consecutive cases treated with imipenem from Sept. 2007 to Sept. 2009 and meropenem within 1 year from Sept. 2008 in Beijing Tiantan Hospital, China. Data including the dosage and duration of the drug use, occurrence of seizures and mortality outcome was collected from the electronic pharmacy records. The incidence of epilepsy, epileptic standardized morbidity rate (SMR) were reported. Attention was paid to the relationship between the use of imipenem/meropenem and the incidence of epilepsy. Results: The imipenem patients within two years amounted to 71, with mean age 45.9±20.2 years, male to female ratio 46/25. The incidence of epilepsy was 11.3% (8 cases). Among them, 1 case occurred during treatment (1/633, 1.6/1000 patient-days), and the remaining 7 cases occurred before treatment (7/2819, 2.5/1000 patient-days), with the standardized incidence rate 0.64, 95% CI (0.08-5.18).The meropenem patients within one year amounted to 92, mean age 45.1±19.4 years, male to female ratio 51/41. The incidence of epilepsy was 6.5% (6 cases). 2 occurred during treatment (2/582, 2.0/1000 patients-hospital days) and 4 before treatment (4/2047, 3.4/1000 patients-inpatient days), standardized incidence rate 1.76, 95% CI (0.32-9.63). Conclusion: Despite many other epileptogenic factors, imipenem or meropenem did not increase the risk of seizures in neurosurgical patients. There was not further risk for patients with pre-existing seizures or creatinine clearance abnormalities when dosed appropriate.


Imipenem, infection, meropenem, neurosurgery, seizures.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 15
Issue Number: 8
First Page: 685
Last Page: 690
Page Count: 6
DOI: 10.2174/1389201015666140717090143
Price: $58
Pharmaceutical Microbiology 2017

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science